<DOC>
	<DOCNO>NCT01581658</DOCNO>
	<brief_summary>The objective study assess effect different degree renal impairment pharmacokinetics , pharmacodynamics safety BI10773 follow oral administration high dose BI10773 single dose Japanese patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Renal Impairment Study Empagliflozin ( BI10773 ) Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes patient Glycosylated haemoglobin &gt; = 6.1 % ( Japan Diabetes Society ) Estimated glomerular filtration rate base modification diet renal diseaseformula screening , &gt; = 15 mL/min/1.73m2 Exclusion criterion : Any evidence significant disease ( renal impairment ) Moderate severe concurrent liver function impairment Gastrointestinal tract surgery , might affect absorption elimination drug Diseases central nervous system ( epilepsy ) , psychiatric disorder , neurological disorder Chronic relevant acute infection Participation another trial investigational drug administration within 30 day prior study drug administration trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>